Canopy Growth downgraded by BofA Securities
$CGC
Medicinal Chemicals and Botanical Products
Health Care
BofA Securities downgraded Canopy Growth from Neutral to Underperform
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/4/2023 | Underperform → Mkt Perform | Bernstein | |
| 11/2/2022 | $1.50 | Underperform | Bernstein |
| 10/26/2022 | Sell → Hold | Canaccord Genuity | |
| 6/8/2022 | Market Perform → Underperform | BMO Capital Markets | |
| 3/22/2022 | Equal Weight → Underweight | Barclays | |
| 3/1/2022 | $14.00 → $9.00 | Equal-Weight | Barclays |
| 2/18/2022 | $9.60 → $11.00 | Neutral | Cantor Fitzgerald |
| 12/22/2021 | Neutral → Underperform | BofA Securities |
424B7 - Canopy Growth Corp (0001737927) (Filer)
424B5 - Canopy Growth Corp (0001737927) (Filer)
EFFECT - Canopy Growth Corp (0001737927) (Filer)